"We hope 2025 is a year of immense progress – not only for Gain but the field as a whole – and look forward to GT-02287 taking one step closer to potentially being the first disease-modifying therapy for #Parkinsons disease" Gene Mack CEO $GANX gaintherapeutics.com/newsroom/press…

Q&A: Gain Therapeutics CEO Discusses AI-Driven Drug Discovery, Strategic Growth Plans $GANX pharmexec.com/view/gain-ther…

Looking forward to presenting at #ADPD2025 $GANX tinyurl.com/msz6pu3d

Cases of #Parkinsons disease set to reach 25 million worldwide by 2050, study suggests. $GANX medicalxpress.com/news/2025-03-c…

Excited to announce we've dosed the first participant in our phase 1b clinical trial of GT-02287 in #Parkinson’s $GANX gaintherapeutics.com/newsroom/press…

We are looking forward to attending the 37th Annual ROTH Conference scheduled March 16-18, 2025 in Dana Point, California. Our CEO Gene Mack will participate in a fireside chat with Roth analyst Boobalan Pachaiyappan, Ph.D. A webcast link will be made available on Monday. $GANX

See the following link for the presentation in 15 minutes. event.summitcast.com/view/YsA9Ty4sR…

The study of GT-02287 is recruiting up to 20 adults with Parkinson's who have either idiopathic disease or known mutations in the GBA1 gene. buff.ly/lVT3xTZ

We are looking forward to joining Lou Basenese tomorrow at 2 pm ET. Please tune in! $GANX #Parkinson's #drugdiscovery #Biotech

Gain Therapeutics Reports Financial Results for the 4th Quarter and Year End 2024 and Provides Corporate Update gaintherapeutics.com/newsroom/press… $GANX

Don't miss out on oral and poster presentations at #ADPD2025 from our very own Joanne Taylor and Raffaella Pozzi! Poster Title: Design of a Phase 1b Study to Evaluate the GCase-Targeting Molecule GT-02287 in GBA1-PD and Sporadic PD $GANX

The AD/PD Conference is currently taking place from April 1–5, 2025, at the Austria Center Vienna in Vienna, $GANX gaintherapeutics.com/the-ad-pd-conf…

We’re excited to be selected to be a part of #NVIDIAConnect and look forward to working with NVIDIA $NVDA to bolster the development of our proprietary Magellan™ next-generation allosteric drug discovery platform. $GANX

Gain Therapeutics Presents Additional Preclinical Data and Design of Phase 1b Clinical Study of GT-02287 at #APDP2025 and Provides Enrollment Update $GANX gaintherapeutics.com/newsroom/press…

We recently shared important updates at the AD/PD 2025 International Conference on #Alzheimer’s and #Parkinson’s Diseases. $GANX gaintherapeutics.com/perspectives/p…

Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on #Parkinson’s Disease and Related Disorders $GANX gaintherapeutics.com/newsroom/press…

Gain Therapeutics to Participate at The Citizens Life Sciences Conference $GANX gaintherapeutics.com/newsroom/press…

Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders $GANX gaintherapeutics.com/newsroom/press…

Catch us in Montreal at the #GBA1 Meeting 2025 for a presentation from CMO Jonas Hannestad. $GANX Track: Small molecules targeting GBA1 Session #2 Presentation Title: Update from Gain Therapeutics Presentation Time: 11:20 a.m. EST Session Date: Thursday, June 5, 2025

Tune into a conversation between Gene Mack, Gain President and CEO, and Donald Tracy from Pharmaceutical Executive. $GANX #Parkinsons pharmexec.com/view/early-tri…